drugset

drugset / Trial / NCT00025454

R115777 in Treating Patients With Advanced Solid Tumors

NCT00025454 ↗

Phase 1 Completed City of Hope Medical Center National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have advanced solid tumors.

Timeline

Start: 2001-08
Primary completion: 2008-07
Completion: 2008-07

Publications

Results Lara PN Jr, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar;16(3):317-21. doi: 10.1097/00001813-200503000-00011.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tipifarnib	Small molecule	300 mg	Oral
Subject	tipifarnib	Small molecule	600 mg	Oral
Subject	tipifarnib	Small molecule	900 mg	Oral
Subject	tipifarnib	Small molecule	1200 mg	Oral
Subject	tipifarnib	Small molecule	1500 mg	Oral
Subject	tipifarnib	Small molecule	1800 mg	Oral

Indications